Table 4.

Characteristics of triple therapies consisting of a PPI, metronidazole and clarithromycin or amoxicillin.

Refs	Combination regimens	Dose	Treatment duration	Eradication rate (ITT)		P
				PUD	NUD
				N/T.N (%)	N/T.N (%)
23	Pan/Met/Cla	40 mg q.d./400 mg b.i.d./250 mg b.i.d.	7 d	54/65 (83.1)	21/24 (87.5)	0.613
23	Pan/Met/Cla	40 mg b.i.d./400 mg b.i.d./250 mg b.i.d.	7 d	54/64 (84.4)	18/22 (81.8)	0.781
24	Ome/Met/Cla	40 mg q.d./500 mg b.i.d./250 mg b.i.d.	7 d	15/19 (78.95)	5/6 (83.3)	0.819
25	Pan/Met/Amo	40 mg b.i.d./500 mg b.i.d./1 g b.i.d.	7 d	14/19 (73.7)	7/11 (63.6)	0.569
26	Ome/Met/Amo	40 mg q.d./400 mg t.i.d.1/750 mg b.i.d.	14 d	22/27 (81.5)	22/37 (59.5)	0.063

Ome, omeprazole; Pan, pantoprazole; Cla, clarithromycin; Amo, amoxicillin; Met, metronidazole; daily; q.d., daily; b.i.d., twice daily. 1Metronidazole was used for 5 d only. PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia.